ArticleWorld journal of urology2026
Clinical characteristics, treatment patterns, and survival outcomes in ductal prostate cancer: a multicenter retrospective analysis.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clarifying risk and treatment trajectories in ductal prostate cancer.World journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstatic ductal adenocarcinoma (PDA) is a rare, aggressive prostate cancer subtype associated with advanced disease and poorer prognosis than acinar adenocarcinoma. Small ductal components influence management and preclude active surveillance. This study analyzed oncologic outcomes and therapeutic patterns in a multicenter German cohort.
methodsRetrospective multicenter cohort, seven high-volume German centers. 82 patients with histologically confirmed PDA diagnosed 2014-2024 included. Histopathological data from biopsy and radical prostatectomy (RP) specimens. CLINICAL DATA: local/systemic treatments, follow-up until 2025. PRIMARY OUTCOME: time to systemic therapy. Secondary: overall survival. Predictors of adverse outcomes assessed via Cox regression.
resultsMost patients presented with d'Amico high-risk (47/82, 57.3%) or intermediate-risk (28/82, 34.2%) disease; 9.8% (8/82) had synchronous metastases. RP performed in 82.9% (68/82), radiotherapy in 7.3% (6/82). Postoperative lymph node positivity and positive surgical margins occurred in 25.0% (17/68) and 22.1% (15/68), respectively. Median follow-up was 36 months (IQR 20-54 months). At the time of analysis, overall survival and cancer-specific survival were immature, with a limited number of events during follow-up. Among patients who required systemic therapy during follow-up, the median interval from local treatment to initiation of systemic therapy was 23 months (IQR 5-31 months). High pre-/postoperative Gleason scores (≥ 8) were associated with earlier initiation of systemic therapy. Among patients receiving systemic treatment (n = 24), ADT monotherapy showed longer median duration (27.2 months) than ARPI (10.9 months) or chemotherapy (6.1 months). LIMITATIONS: retrospective design, limited sample size.
conclusionPDA demonstrates aggressive behavior with early need for systemic therapeutic escalation in a substantial proportion. High Gleason scores were associated with earlier initiation of systemic therapy. These findings suggest that PDA should be considered a high-risk entity. However, survival outcomes require longer follow-up for definitive conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.